Expression and Prognostic Value of PIK3CA, VEGF, IL-8, IL-10, and RIP2 in Diffuse Large B-Cell Lymphoma

Table 3

Multivariate Cox proportional hazard regression analysis of prognosis.

Clinical features	b	Sb	Wald χ^2	HR	95% CI	value
Ann Arbor Stage
I, II vs. III, IV	0.575	0.206	6.231	1.654	1.234–2.564	0.009
B symptoms
Presence vs. absence	0.765	0.409	3.721	2.134	1.064–3.342	0.062
Extranodal site
≤1 vs. >1	1.532	0.387	23.954	4.576	2.289–6.041	<0.001
Serum LDH level (U/L)
<245 vs. ≥245	0.621	0.231	7.674	1.674	1.121–2.675	0.006
IPI scores
0–2 vs. 3–5	1.813	0.874	13.276	5.231	2.753–8.976	<0.001
ECOG scores
0-1 vs. ≥2	1.033	0.268	4.409	2.276	1.673–4.321	0.023
Bone marrow involvement
Presence vs. absence	1.039	0.159	14.762	2.429	1.531–4.652	<0.001
Extranodal involvement
Presence vs. absence	1.896	0.127	4.201	6.721	2.187–15.543	0.431
VEGF level
Low vs. high	1.109	0.0281	14.289	3.041	1.762–5.091	<0.001
PIK3CA
Negative vs. positive	1.659	0.673	2.369	5.187	1.398–8.971	0.019
IL-8 level
Low vs. high	0.573	0.268	4.291	1.782	1.021–3.009	0.034
IL-10 level
Low vs. high	0.765	0.352	5.728	2.179	1.128–4.098	0.012
RIP2
Negative vs. positive	0.567	0.278	4.163	1.765	1.017–3.021	0.039

DLBCL, diffuse large B-cell lymphoma; LDH, lactate dehydrogenase; GCB, germinal center B-cell; IPI, international prognostic index; ECOG, eastern cooperative oncology group; PIK3CA, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha; VEGF, vascular endothelial growth factor; IL, interleukin; RIP2, receptor-interacting protein-2; HR, hazard ratio; CI, confidence interval.